Key Takeaway: Bioavailability is the difference between a supplement that works and one that is wasted
The Truth Emerges On July 29, 2025, Novo issued a press release and held a conference call lowering its sales and profit outlook for 2025, citing "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Management also noted that despite the expiry of the FDA grace period for mass compounding on May 22, 2025, company research showed that unsafe and unlawful mass compounding continued
The goal is to restore functional signaling
Mounjaro (tirzepatide) mimics the effects of the natural gut hormones that help control blood sugar and appetite
Jonathan Abbott, who acknowledges in his presentations before veterinary groups that: "the value of ACE inhibitors in dogs with subclinical (asymptomatic) valvular disease is uncertain [citing the SVEP and VETPROOF studies]
That, he told lawmakers, was pretty much a non-starter